

Dyslipidemia

Saturday, November 1, 2014
1:41 PM

Learning Objectives:

- 3 pathways of lipid transport & metabolism
 - exogenous
 - endogenous
 - reverse cholesterol transport
- main lipoproteins involved in lipid transport & metabolism
- primary vs. secondary dyslipidemia
- primary defect of dyslipidemia
- atherogenesis development/progression & complications
- targets for treatment of dyslipidemia

Epidemiology

- leading cause in morbidity/mortality (CVD, cancer, etc)
- ↑ cholesterol, ↑ heart issues

CHOLESTEROL - cell membrane formation, hormone synth, source of FAs

$$TC = LDL + HDL + (TG/5)$$

Total Cholesterol



- 1) LDL-C (60-70%) - most atherogenic
- 2) HDL-C
- 3) TRIGLYCERIDES - major component of CHYLOMICRONS; major source of energy; atherogenic

TG, LDL = atherogenic

Classes of Lipoproteins

LIPOPROTEIN - complexes used to transport lipids via lymph & blood


	Density	%TG
Chylo	<0.94	80-95
VLDL	0.94-1.006	55-80
IDL	1.006-1.019	23-30
LDL	1.019-1.063	5-15
HDL	1.063-1.21	5-10



Lipid Disorders


- LIPID DISORDER - defect in lipoprotein synth/processing/clearance
- DYSLIPIDEMIA = hyperlipidemia = hypercholesterolemia
 - ↑ TC/LDL/TG, ↓ HDL

Pathways of Lipid Transport



MTP - transfer protein

LPL - enzyme in blood/lymph that converts (Chylo → Chylo Remnant)/(VLDL → IDL)



Involved in Lipid Disorders

- 1) LDLR
- 2) PCSK9 gene mutation
- 3) Apo B
- 4) LPL
- 5) Apo C
- 6) SR
- 7) LCAT
- 8) CEPT

LDLR - receptor for LDL

Liver Cells	- cholesterol excretion
Extrahepatic/Peripheral Cells	- LDL is broken down to release cholesterol, which is used by cell, stored, or excreted

PCSK9 - protein that destroys LDLR (liver); dominant

↑ PCSK9 ↓ LDLR* ↑ cholesterol (hyper)

APOLIPOPROTEINS (A, B,C,E) - membrane-bound proteins of lipoproteins

- stabilize membrane
- cofactors
- interacts with receptors to promote lipid metabolism

APO B - estimates #atherogenics

	Location	Lipoprotein	Function
APO B-48	Intestine	Chylo	- Chylo secretion
APO B-100	Liver	VLDL, IDL, LDL	- VLDL secretion - <u>LDL ligand</u>

*B-100 competes with LDL for LDLR, prolonging LDL life & ↑LDL oxidation

LPL - H₂O-soluble enzyme on capillary wall; TG (Chylo & VLDL) → (2 FAs + 1 monoacylglycerol)

APO C2	activates LPL	(bound to Chylo & VLDL)
APO C3	inhibits LPL	

LDL Oxidation

1) LDL oxidized by free radicals Cu²⁺/Fe²⁺

↑ plasminogen inhibitor	coagulation
↑ endothelin	vasoconstriction
↓ NO	vasoconstriction, platelet promotion


2) oxLDL binds CD36

3) taken up by macrophage → "foam cell" formation

4) cholesterol put under endothelium

5) *ARTHERO*

CD36 - macrophage "scavenger receptor"; binds oxLDL
ATHEROGENESIS/ATHEROSCLEROSIS - hardening of blood vessels, puss & platelet aggregation, vessel narrowing




HDL - liver & intestine; "cardioprotective"; involved in Reverse Cholesterol Transport

- Reverse Cholesterol Transport - HDL-mediated transport of cholesterol (heart → liver)

Reverse Cholesterol Transport:

<http://www.youtube.com/watch?v=0h18qa5hTZU>



LCAT - Cholesterol → CE

SR-B1 - liver "scavenger receptor"; binds HDL

CETP - exchanges CE & TGs between lipoproteins

Dyslipidemia Classifications

FREDERICKSON CLASSIFICATION - based on genetic makeup; no longer used

PRACTICAL CLASSIFICATION - primary vs. secondary

	Elevations	Causes	
Primary ("Familial")	LDL/TG	- <u>gene mutations</u> : - LDLR - LDLR adapter protein - Apo B - PCSK9 - <u>xanthomas/atheromas</u> - <u>rare</u> : premature/fatal CHD <20 yrs	Symptoms: - xanthomas/atheromas - pancreatitis, abdominal pain, hepatosplenomegaly - TG > 1,000 > 10,000
Secondary (common)	LDL/TG	- obesity - diet - DM - alcohol - Liver disease - anabolic steroids - anorexia - smoking - hypothyroidism	4 Risk Groups: 1) CVD 2) (190 < LDL) 3) (70 < LDL > 189) + (DM (40-75 yrs)) 4) (70 < LDL > 189) + (CVD 10 Risk > 7.5%)

XANTHOMAS - clumping of LDL-C in tendons
ATHEROMAS - clumping of LDL-C in arteries

CVD - ACS, MI, angina, revascularization, stroke, TIA, PAD

Treatments

- diet
- bile acids reabsorption
- PCSK9
- De Novo (HMG-CoAR)
- LDLR
- MTP
- Apo B

Complications

